MARKHAM, Ontario, March 5, 2007 (PRIME NEWSWIRE) (PRIMEZONE) -- AlphaRx (OTCBB:ALRX) announced today the completion of the treatment phase of the double-blind, placebo & vehicle-controlled, randomized and multi-center Phase II clinical trial, to measure the efficacy and safety of Indaflex(tm) for the treatment of Osteoarthritis of the knee. Currently, no prescription strength topical NSAID for the treatment of arthritis is approved for sale in the U.S.
